Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LOWELL L HART

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1245221993
CMS profile
55830
Location
FORT MYERS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$9,319.11

214 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $2,319.08 10
PFIZER INC. $1,369.97 8
Boehringer Ingelheim International GmbH $1,057.63 1
NOVARTIS PHARMACEUTICALS CORPORATION $667.27 19
Merck Sharp & Dohme LLC $604.94 18
Seagen Inc. $332.25 15
Exelixis Inc. $215.84 6
Gilead Sciences, Inc. $174.71 10
E.R. Squibb & Sons, L.L.C. $163.36 9
Bayer Healthcare Pharmaceuticals Inc. $159.37 22
Spectrum Pharmaceuticals Inc. $158.27 1
Celgene Corporation $156.91 8
Eisai Inc. $146.65 7
BeiGene USA, Inc. $143.68 8
CTI BioPharma Corp. $142.97 2
Janssen Biotech, Inc. $131.33 9
Ipsen Biopharmaceuticals, Inc $125.04 1
Incyte Corporation $93.75 4
Mirati Therapeutics, Inc. $70.27 4
TerSera Therapeutics LLC $67.94 2
GENZYME CORPORATION $59.23 3
Boehringer Ingelheim Pharmaceuticals, Inc. $57.72 3
GlaxoSmithKline, LLC. $56.21 3
Genentech USA, Inc. $54.89 3
Pharmacyclics LLC, An AbbVie Company $53.48 2
Daiichi Sankyo Inc. $51.29 3
Adaptive Biotechnologies Corporation $44.04 1
Takeda Pharmaceuticals U.S.A., Inc. $43.30 2
Astellas Pharma US Inc $40.61 2
PharmaEssentia USA Corporation $39.18 2
MENARINI SILICON BIOSYSTEMS, INC. $37.54 1
SOBI, INC $37.05 2
Amgen Inc. $36.17 1
Kite Pharma, Inc. $34.12 2
MorphoSys, US Inc. $32.05 2
Sumitomo Pharma America, Inc. $30.43 2
Epizyme, Inc. $22.97 1
Myriad Genetic Laboratories, Inc. $22.94 1
Lilly USA, LLC $22.46 1
Stemline Therapeutics Inc. $22.29 1
Alnylam Pharmaceuticals Inc. $22.07 1
EMD Serono, Inc. $20.91 1
Kyowa Kirin, Inc. $20.80 1
JAZZ PHARMACEUTICALS INC. $19.48 1
ADC Therapeutics America, Inc. $18.83 1
Puma Biotechnology, Inc. $18.82 1
ARRAY BIOPHARMA INC $18.25 1
ImmunoGen, Inc. $17.99 1
AVEO Pharmaceuticals, Inc. $16.65 1
Alexion Pharmaceuticals, Inc. $16.64 1
Acrotech Biopharma Inc. $15.55 1
SERVIER PHARMACEUTICALS LLC $13.92 1

Page 3 of 5; records 101–150 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LOWELL L HART

NPI 1245221993 · CMS profile ID 55830

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

FORT MYERS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245221993?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LOWELL L HART, NPI 1245221993, CMS profile ID 55830. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245221993?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LOWELL L HART, NPI 1245221993, CMS profile ID 55830. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245221993?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LOWELL L HART, NPI 1245221993, CMS profile ID 55830, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1245221993?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

214 matching records · $9,319.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 214 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 214.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eisai Inc. $13.9806/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023320275 CMS
GlaxoSmithKline, LLC. $23.3506/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002888515 CMS
Exelixis Inc. $14.2206/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044574239 CMS
Janssen Biotech, Inc. $16.8006/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988084367 CMS
Incyte Corporation $23.7006/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044328239 CMS
Novartis Pharmaceuticals Corporation $19.7006/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991990217 CMS
Novartis Pharmaceuticals Corporation $12.4306/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991990209 CMS
Puma Biotechnology, Inc. $18.8206/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059046689 CMS
Seagen Inc. $12.8606/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995674735 CMS
Gilead Sciences, Inc. $19.7806/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025824173 CMS
Merck Sharp & Dohme LLC $18.1306/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048399787 CMS
Celgene Corporation $15.8306/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016081023 CMS
BeiGene USA, Inc. $15.0706/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051178185 CMS
Seagen Inc. $13.8306/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995674715 CMS
Novartis Pharmaceuticals Corporation $3.2606/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991990226 CMS
Amgen Inc. $36.1706/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020626453 CMS
MENARINI SILICON BIOSYSTEMS, INC. $37.5406/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038556899 CMS
Adaptive Biotechnologies Corporation $44.0406/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022974089 CMS
Novartis Pharmaceuticals Corporation $129.9206/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991990193 CMS
Celgene Corporation $23.1706/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016081033 CMS
Mirati Therapeutics, Inc. $16.4306/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057992459 CMS
AstraZeneca Pharmaceuticals LP $20.8105/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015180777 CMS
Bayer Healthcare Pharmaceuticals Inc. $0.3005/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000688503 CMS
Bayer Healthcare Pharmaceuticals Inc. $9.5105/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000688983 CMS
Pharmacyclics LLC, An AbbVie Company $28.9105/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998286839 CMS
GENZYME CORPORATION $25.9505/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049692911 CMS
Seagen Inc. $13.8305/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995674687 CMS
Daiichi Sankyo Inc. $17.1705/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006427637 CMS
PFIZER INC. $28.8005/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050547969 CMS
Celgene Corporation $25.0905/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016081009 CMS
Ipsen Biopharmaceuticals, Inc $125.0405/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045459255 CMS
BeiGene USA, Inc. $15.9105/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051178187 CMS
Incyte Corporation $21.0805/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044328189 CMS
Merck Sharp & Dohme LLC $124.9805/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048399659 CMS
Novartis Pharmaceuticals Corporation $10.9105/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991990215 CMS
EMD Serono, Inc. $20.9105/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032334961 CMS
Celgene Corporation $14.9605/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016081003 CMS
Genentech USA, Inc. $15.7305/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040440137 CMS
Kyowa Kirin, Inc. $20.8005/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027007571 CMS
Merck Sharp & Dohme LLC $24.7305/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048399645 CMS
Myriad Genetic Laboratories, Inc. $22.9405/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776849 CMS
Bayer Healthcare Pharmaceuticals Inc. $10.4405/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000689069 CMS
Celgene Corporation $17.9005/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016080999 CMS
PFIZER INC. $1,250.0004/28/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049443675 CMS
MorphoSys, US Inc. $16.4504/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060324279 CMS
AstraZeneca Pharmaceuticals LP $124.9804/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011553123 CMS
Exelixis Inc. $21.3504/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044541342 CMS
Astellas Pharma US Inc $23.7504/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034054257 CMS
Exelixis Inc. $124.9804/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044540008 CMS
Gilead Sciences, Inc. $11.5904/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026060943 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $159,454.16 320
PY2020 $51,099.07 191
PY2021 $8,963.12 135
PY2022 $6,212.96 188
PY2023 $9,319.11 214
PY2024 $13,424.25 214
PY2025 $8,048.20 179

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $507.10 1
PY2025 Principal investigator $153,752.63 19
PY2024 Recipient $6,060.58 1
PY2024 Principal investigator $170,181.16 21
PY2023 Recipient $5,308.73 4
PY2023 Principal investigator $623,520.25 52
PY2022 Recipient $965.00 1
PY2022 Principal investigator $1,282,018.27 45
PY2021 Recipient $2,305.97 2
PY2021 Principal investigator $3,036,583.82 113
PY2020 Recipient $5,480.00 3
PY2020 Principal investigator $3,520,244.24 139
PY2019 Recipient $631.79 2
PY2019 Principal investigator $1,040,624.39 114

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $128.00 11/24/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228729916
Principal investigator 1 PFIZER INC. $928.00 11/24/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228739265
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,617.33 11/11/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190305863
Principal investigator 1 PFIZER INC. $332.80 10/06/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228756909
Principal investigator 1 PFIZER INC. $192.00 07/28/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228765491
Principal investigator 1 PFIZER INC. $4,128.00 07/28/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228768393
Principal investigator 1 AstraZeneca UK Limited $6,400.00 06/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291) No dispute reported 06/30/2026 1185542882
Principal investigator 1 PFIZER INC. $332.80 06/09/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228792149
Recipient Novartis Pharmaceuticals Corporation $507.10 06/01/2025 Covered Recipient Physician CLEE011O12301C No dispute reported 06/30/2026 1190291841
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,575.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185542880
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,900.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185542872
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,600.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291) No dispute reported 06/30/2026 1185542874
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,425.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) No dispute reported 06/30/2026 1185542884
Principal investigator 1 Novartis Pharmaceuticals Corporation $600.00 03/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
SOLAR1 A phase III randomized double blind placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive HER2 negative advanced breast cancer which progressed on or after aromatase in No dispute reported 06/30/2026 1190304447
Principal investigator 1 PFIZER INC. $750.00 02/18/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228784225
Principal investigator 1 PFIZER INC. $704.00 02/18/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228789689
Principal investigator 1 PFIZER INC. $665.60 02/10/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228797402
Principal investigator 1 Novartis Pharmaceuticals Corporation $100,274.10 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190305865
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,600.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185542878
Principal investigator 1 AstraZeneca UK Limited $5,600.00 01/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291) No dispute reported 06/30/2026 1185542876